Evidence map›Paper›PMID 38903094›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Development of a predictive algorithm for patient survival after traumatic injury using a five analyte blood panel.

Parinaz Fathi, Maria Karkanitsa, Adam Rupert, Aaron Lin, Jenna Darrah, F Dennis Thomas, Jeffrey Lai, Kavita Babu, Mark Neavyn, Rosemary Kozar and 7 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Parinaz FathiSection on Immunoengineering, Center for Biomedical Engineering and Technology Acceleration, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD 20892.
Maria KarkanitsaSection on Immunoengineering, Center for Biomedical Engineering and Technology Acceleration, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD 20892.
Adam RupertAIDS Monitoring Laboratory, Frederick National Laboratory for Cancer Research, Frederick MD.
Aaron LinSection on Immunoengineering, Center for Biomedical Engineering and Technology Acceleration, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD 20892.
Jenna DarrahDunlap and Associates, Inc., Cary, NC, 27511.
F Dennis ThomasDunlap and Associates, Inc., Cary, NC, 27511.
Jeffrey LaiDepartment of Emergency Medicine, University of Massachusetts Medical School, Worcester MA 01655.
Kavita BabuDepartment of Emergency Medicine, University of Massachusetts Medical School, Worcester MA 01655.
Mark NeavynDepartment of Emergency Medicine, University of Massachusetts Medical School, Worcester MA 01655.
Rosemary KozarShock Trauma Center, University of Maryland School of Medicine, Baltimore MD 21201.
Christopher GriggsDepartment of Emergency Medicine, Atrium Health's Carolinas Medical Center, Charlotte NC 28203.
Kyle W CunninghamDivision of Acute Care Surgery, Atrium Health's Carolinas Medical Center, Charlotte NC 28203.
Carl I SchulmanUniversity of Miami Miller School of Medicine, Miami FL 33136.
Marie CrandallDepartment of Surgery, University of Florida College of Medicine, Jacksonville FL 33209.
Irini SeretiLaboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases (NIAID), NIH.
Emily RicottaEpidemiology and Data Management Unit, Laboratory of Clinical Immunology and Microbiology, NIAID, NIH, Bethesda, MD 20892.
Kaitlyn SadtlerSection on Immunoengineering, Center for Biomedical Engineering and Technology Acceleration, National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH), Bethesda, MD 20892.ORCID 0000-0003-2587-8330

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe trauma can induce systemic inflammation but also immunosuppression, which makes understanding the immune response of trauma patients critical for therapeutic development and treatment approaches. By evaluating the levels of 59 proteins in the plasma of 50 healthy volunteers and 1000 trauma patients across five trauma centers in the United States, we identified 6 novel changes in immune proteins after traumatic injury and further new variations by sex, age, trauma type, comorbidities, and developed a new equation for prediction of patient survival. Blood was collected at the time of arrival at Level 1 trauma centers and patients were stratified based on trauma level, tissues injured, and injury types. Trauma patients had significantly upregulated proteins associated with immune activation (IL-23, MIP-5), immunosuppression (IL-10) and pleiotropic cytokines (IL-29, IL-6). A high ratio of IL-29 to IL-10 was identified as a new predictor of survival in less severe patients with ROC area of 0.933. Combining machine learning with statistical modeling we developed an equation ("VIPER") that could predict survival with ROC 0.966 in less severe patients and 0.8873 for all patients from a five analyte panel (IL-6, VEGF-A, IL-21, IL-29, and IL-10). Furthermore, we also identified three increased proteins (MIF, TRAIL, IL-29) and three decreased proteins (IL-7, TPO, IL-8) that were the most important in distinguishing a trauma blood profile. Biologic sex altered phenotype with IL-8 and MIF being lower in healthy women, but higher in female trauma patients when compared to male counterparts. This work identifies new responses to injury that may influence systemic immune dysfunction, serving as targets for therapeutics and immediate clinical benefit in identifying at-risk patients.

Identifiers

PMID38903094
PMCPMC11188118

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.